Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV alteplase for acute central retinal artery occlusion
2017-002061-22Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in central retinal artery occlusion (CRAO) comparing IV alteplase with Placebo / double-dummy control (2 arms). Primary endpoint: Visual acuity improvement at 1 month. Started Jun 2017; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on 2017-002061-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002061-22.